AI Article Synopsis
- The study explored specific gene polymorphisms related to cancer susceptibility and treatment response in ovarian cancer patients, focusing on GSTT1, GSTM1, GSTO2, GSTP1, and p53 genes.
- A comparison was made between 69 ovarian cancer patients and 222 healthy women, with a particular follow-up on patients who underwent platinum-based chemotherapy.
- The findings indicated no link between the GST genes and ovarian cancer risk, but a specific p53 genotype significantly increased the risk of developing ovarian cancer by over 2.5 times.
Article Abstract
Purpose: A series of polymorphisms in germ-line DNA have been investigated in an effort to delineate polygenic models of cancer susceptibility and prognosis. As low-penetrance susceptibility genes may combine additively or multiplicatively and contribute to cancer incidence and to the response to chemotherapy, we studied GSTT1, GSTM1, GSTO2, GSTP1 and codon 72 of p53 genotype profiles in ovarian cancer patients.
Methods: We compared 69 ovarian cancer patients with 222 control healthy women paired for ethnic and life-style characteristics. Outcome was evaluated in 29 stage III and IV patients submitted to a platinum-based chemotherapy followed-up for 6-29 months (17 +/- 9 months).
Results: GSTT1, GSTM1, GSTO2 and GSTP1 genes presented a similar genotype distribution, but codon 72 of p53 gene wild-type variant was less frequent in ovarian cancer patients than in controls (chi(2); P = 0.0004).
Conclusions: We were unable to demonstrate any association between the GST genotypes studied and the risk of ovarian cancer but the inheritance of a heterozygous Arg/Pro genotype of p53 increased the risk of ovarian cancer more than 2.5 times (OR = 2.571; 95% CI = 1.453-4.550). There was no association of the studied genes to any clinical or pathological feature of the patients or to their response to chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00432-006-0099-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Corrigendum: Assessing the impact of contraceptive use on reproductive cancer risk among women of reproductive age-a systematic review.
Front Glob Womens Health
December 2024
WHO Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
[This corrects the article DOI: 10.3389/fgwh.2024.
View Article and Find Full Text PDFEditorial: Advances toward improved understanding and treatment of uncommon ovarian cancer types and subtypes.
Front Oncol
December 2024
Department of Gynaecologic Oncology, Center for Gynaecologic Oncology Amsterdam, Cancer Center Amsterdam, Amsterdam University Medical Centres, Amsterdam, Netherlands.
Classification and risk assessment of ovarian-adnexal lesions using parametric and radiomic analysis of co-registered ultrasound-photoacoustic tomographic images.
Photoacoustics
February 2025
Biomedical Engineering Department, Washington University in St Louis, United States.
Ovarian-adnexal lesions are conventionally assessed with ultrasound (US) under the guidance of the Ovarian-Adnexal Reporting and Data System (O-RADS). However, the low specificity of O-RADS results in many unnecessary surgeries. Here, we use co-registered US and photoacoustic tomography (PAT) to improve the diagnostic accuracy of O-RADS.
View Article and Find Full Text PDFUtilization of immunohistochemistry in gynecologic tumors: An expert review.
Gynecol Oncol Rep
December 2024
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Long Island Jewish Medical Center, Zucker School of Medicine at Hofstra/Northwell, Northwell Health, New Hyde Park, NY, United States.
The use of immunohistochemistry (IHC) and molecular pathology has been widely adopted over the past 3 decades and has aided in the precision of diagnosing gynecologic tumors. While many tumors can be diagnosed by histologic appearance on routine hematoxylin and eosin stained slides, the use of IHC has dramatically changed practice, leading to a better understanding and subtyping of gynecologic tumors. This detailed classification of tumors has aided in the implementation and development of targeted therapies.
View Article and Find Full Text PDFTrace element zinc metabolism and its relation to tumors.
Front Endocrinol (Lausanne)
December 2024
Department of Urology, Kunming Children's Hospital, Kunming, Yunnan, China.
Zinc is an essential trace element in the human body, playing a crucial role in cellular metabolism.Dysregulation of zinc homeostasis can lead to abnormal cellular metabolism, contributing to diseases and closely related to tumor development. Adequate zinc intake can maintain zinc homeostasis in the body and support normal cellular metabolism.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!